Chimeric antigen receptor (CAR) T-cell therapies have transformed patient outcomes and treatment approaches for patients with difficult-to-treat hematologic malignancies leading to improved overall survival. However, the use of CAR T-cell therapies is challenging, requiring careful patient selection, prolonged treatment at an authorized treatment center, and ongoing monitoring and support provided by an interprofessional, multidisciplinary care team in the community and treatment center settings. This activity highlights key concepts in managing patients treated with CAR T-cell therapy, provides an overview of the principles of interprofessional collaboration, and describes the importance of close communication and collaboration, particularly during the transition from treatment center back to the community setting.
Course Credit:
0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours
Dates:
Opens: 2026-02-05
Closes: 2027-02-05
Target Audience:
Nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients treated with CAR T-cell therapy.
This activity was self-funded by Annenberg Center for Health Sciences.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Chris Elder, PharmD, BCOP (Planner)Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and Pharmacosmos
Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.
Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Christopher Flores, MD
Family Medicine Physician
Eisenhower Medical Center
Rancho Mirage, California -
LaTosha Mollette, DNP
Family Nurse Practitioner
Louisiana Family Medicine Clinic
Jonesboro, Louisiana -
Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York -
Michael Smith, PharmD
Clinical Pharmacist in Pain/Palliative Care
University of Michigan
Ann Arbor, Michigan
Presenting Faculty
Learning Objectives
- Describe the evolution in the understanding of CAR T-cell therapy
- Identify strategies to improve interprofessional care of patients treated with CAR T-cell therapy
Faculty Disclosures
Christopher Flores, MD
No relationships to disclose.LaTosha Mollette, DNP
No relationships to disclose.Gilles Salles, MD, PhD
Advisory Board: AbbVie, BMS, Genentech, Genmab, Kite Gilead, Novartis, Pfizer
Data Monitoring Safety Board: BeiGene